MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
VolitionRx Limited Interest Expense 2011-2026 | VNRX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.76 M | -233 K | 311 K | - | - | 130 K | 127 K | -111 K | 73.1 K | 20.4 K | -15.7 K | 14.8 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 311 K | -1.76 M | -145 K |
Quarterly Interest Expense VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -309 K | -16.3 K | 45.1 K | - | 129 | -69.8 K | - | - | - | - | - | - | - | - | 41 K | - | 38.8 K | 39.7 K | 42.2 K | - | 34.7 K | 22.6 K | 33.8 K | - | 32.3 K | 33.1 K | -30.1 K | - | -29.1 K | 26.6 K | 23 K | - | 17.6 K | 20.4 K | 12.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.1 K | -309 K | 437 |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 117.5 | 2.1 % | $ 35.7 B |  USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.83 | 4.86 % | $ 897 M | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.2 | -4.35 % | $ 9.73 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.45 | 5.84 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.53 | 1.73 % | $ 654 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 178.34 | 1.53 % | $ 8.84 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.59 | 5.52 % | $ 425 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 501.23 | 1.56 % | $ 14.5 B | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.0 | 4.03 % | $ 1.02 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 195.87 | 3.3 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 126.96 | 4.99 % | $ 20.2 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.3 | 6.03 % | $ 463 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.72 | 0.6 % | $ 280 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 82.21 | 4.59 % | $ 10.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.85 | 5.95 % | $ 92.5 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.08 | -2.8 % | $ 4.78 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.55 | 0.87 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 110.37 | 3.33 % | $ 9.1 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.64 | 0.02 % | $ 2.68 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.18 | 1.25 % | $ 22 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 201.9 | 4.6 % | $ 19.9 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 120.4 | 2.78 % | $ 5.63 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.39 | 2.96 % | $ 91.7 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 81.67 | 1.34 % | $ 5.51 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 192.91 | 0.73 % | $ 21.4 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.14 | -2.97 % | $ 1.98 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 5.19 | 5.06 % | $ 4.08 M | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |